Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and Stimulator for Interferon Genes (STING) modulators as cancer immunotherapeutics
In its many embodiments, the present invention provides a novel class of indolines as inhibitors of α2C adrenergic receptor agonists, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the α2C adrenergic receptors using such compounds or pharmaceutical compositions.
作者:Dmitry I. Bugaenko、Alexey A. Volkov、Alexander V. Karchava
DOI:10.1021/acs.joc.3c00734
日期:2023.7.21
Most existing methods for the synthesis of alkylaryl thioethers require the use of mercaptans as the starting materials, which comes with practical limitations. Reactions of diaryliodonium salts with xanthate salts, easily prepared from the corresponding alcohols and CS2, under the developed conditions represent an operationally simple, thiol-free method for the synthesis of these valuable compounds
大多数现有的烷基芳基硫醚的合成方法需要使用硫醇作为起始原料,这存在实际限制。二芳基碘鎓盐与黄原盐(很容易由相应的醇和CS 2制备)在开发的条件下的反应代表了一种操作简单、无硫醇的合成这些有价值的化合物的方法。该方案具有高官能团耐受性,可应用于后期 C-H 官能化和 CD 3 S 基团的引入。
Substituted-3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and stimulator for interferon genes (STING) modulators as cancer immunotherapeutics
申请人:Stingray Therapeutics, Inc.
公开号:US11142524B2
公开(公告)日:2021-10-12
Substituted -3H-imidazo[4,5-c]pyridine and 1H-pyrrolo[2,3-c]pyridine series of novel Ectonucleotide Pyrophosphatase/Phosphodiesterase-1 (ENPP1) and related compounds, which are useful as inhibitors of ENPP1; synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds and compositions to treat disorders associated with dysfunction of the ENPP1.